Development and validation of a Bayesian survival model for inclusion body myositis
Abstract Background Associations between disease characteristics and payer-relevant outcomes can be difficult to establish for rare and progressive chronic diseases with sparse available data. We developed an exploratory bridging model to predict premature mortality from disease characteristics, and...
Main Authors: | Gorana Capkun, Jens Schmidt, Shubhro Ghosh, Harsh Sharma, Thomas Obadia, Ana de Vera, Valery Risson, Billy Amzal |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Theoretical Biology and Medical Modelling |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12976-019-0114-4 |
Similar Items
-
Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras
by: Boel De Paepe
Published: (2019-01-01) -
Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers
by: Jana Buzkova, et al.
Published: (2018-12-01) -
Sporadic inclusion body myositis in the rheumatology clinic
by: Fernando Henrique Carlos de Souza, et al.
Published: (2020-01-01) -
Inclusion Body Myositis Treated with Alemtuzumab
by: Juliana Sá, et al.
Published: (2019-12-01) -
Multicenter questionnaire survey for sporadic inclusion body myositis in Japan
by: Naoki Suzuki, et al.
Published: (2016-11-01)